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Renal transplantation is the standard of care for patients with end-stage renal dis-
ease. Although maintenance immunosuppression with calcineurin inhibitors yields
excellent one-year survival, it is associated over the long term with high rates of death
and graft loss, owing in part to the adverse renal, cardiovascular, and metabolic effects
of these agents. The use of potentially less toxic agents, such as belatacept, a selective




We randomly assigned renal-transplant recipients to receive an intensive or a less-
intensive regimen of belatacept or cyclosporine. All patients received induction therapy
with basiliximab, mycophenolate mofetil, and corticosteroids. The primary objective
was to demonstrate the noninferiority of belatacept over cyclosporine in the incidence
of acute rejection at six months (with an upper bound of the 95 percent confidence in-




At six months, the incidence of acute rejection was similar among the groups: 7 per-
cent for intensive belatacept, 6 percent for less-intensive belatacept, and 8 percent for
cyclosporine. At 12 months, the glomerular filtration rate was significantly higher with
both intensive and less-intensive belatacept than it was with cyclosporine (66.3, 62.1,




, respectively), and chronic allograft nephropathy
was less common with both regimens of belatacept than with cyclosporine (29 per-
cent, 20 percent, and 44 percent, respectively). Lipid levels and blood-pressure values
were similar or slightly lower in the belatacept groups, despite the greater use of lipid-




Belatacept, an investigational selective costimulation blocker, did not appear to be in-
ferior to cyclosporine as a means of preventing acute rejection after renal transplan-
tation. Belatacept may preserve the glomerular filtration rate and reduce the rate of
chronic allograft nephropathy.
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belatacept for immunosuppression in renal-transplant recipients
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enal transplantation, the stan-
 
dard of care for patients with end-stage





 Current regimens of immunosup-
pression yield excellent one-year rates of patient
and graft survival; however, five-year survival rates
among recipients of kidneys from cadaveric donors





 Paradoxically, the com-
monly used calcineurin inhibitors, effective for im-
munosuppression, contribute to late allograft loss
and death. Calcineurin inhibitors are nephrotoxic
and have adverse effects on blood pressure, lipid lev-





inhibitors promote cardiovascular disease, the most
common cause of death among transplant recip-
ients, as well as chronic allograft nephropathy, the





 A current challenge in renal
transplantation is to develop immunosuppressive
regimens that protect against rejection as well as
calcineurin inhibitors do but without the adverse
renal and cardiovascular effects.
Belatacept (LEA29Y), a selective costimulation
blocker, binds surface costimulatory ligands (CD80
and CD86) of antigen-presenting cells. In the con-
text of antigen recognition (signal 1), the interac-
tion of CD80 and CD86 with the surface costimula-
tory receptor CD28 of T cells (signal 2) is required
for full activation of T cells. Blockade of signal 2 in-





 Belatacept was derived from abatacept,
a human fusion protein combining the extracellu-
lar portion of cytotoxic T-lymphocyte–associated
antigen 4 (CTLA4) with the constant-region frag-
ment (Fc) of human IgG1 (CTLA4Ig). Although
abatacept is an efficacious treatment for T-cell–









 it is an ineffective
means of prophylaxis against rejection in nonhu-





cept differs from abatacept by two specific amino-
acid substitutions, thus conferring greater binding
avidity to CD80 and CD86, more potent inhibition
of T-cell activation, and effective rejection prophy-




 The primary objec-
tive of this study was to demonstrate the noninferi-
ority of belatacept over cyclosporine with respect to





The study was a partially blinded, randomized, par-
allel-group, multicenter, phase 2 study with an ac-
tive control and was conducted at 22 centers in the
United States, Canada, and Europe between March
2001 and December 2003. Drs. Hagerty, Vincenti,
Larsen, and Charpentier designed the protocol and
the trial. Drs. Vincenti, Larsen, Durrbach, Wekerle,
Nashan, Lang, Grinyo, Halloran, Solez, Blancho,
and Charpentier as well as other members of the
Belatacept Study Group collected data. Data were
analyzed and primarily vouched for by Drs. Zhou,
Natarajan, Nashan, Levy, Halloran, Vincenti, Larsen,
and Charpentier and reviewed by all other authors.
The manuscript was written by Drs. Levy, Vincenti,
Larsen, and Charpentier and critically reviewed and
revised by the other authors. The data were held
by Bristol-Myers Squibb. A data and safety moni-
toring board assessed overall safety in an unblind-





Adult recipients of a renal allograft from a non–
HLA-identical living or deceased donor were eligi-
ble. Patients who had previously undergone renal
transplantation, patients with a history of a panel-
reactive antibody titer exceeding 20 percent, and
patients deemed at increased risk for acute rejec-
tion by an investigator could make up no more than
10 percent of the study population and were con-
sidered higher-risk patients. The following charac-
teristics were exclusion criteria: underlying renal
disease in the recipient that could recur in the al-
lograft, including focal and segmental glomerulo-
sclerosis, type I or II membranoproliferative glomer-
ulonephritis, the hemolytic–uremic syndrome, and
thrombotic thrombocytopenic purpura; active hep-
atitis B or C or any other infection that would nor-
mally preclude transplantation; human immuno-
deficiency virus infection; a history of or evidence
of cancer; a positive T-cell lymphocytotoxic cross-
match with the use of donor lymphocytes and re-
cipient serum; a history of drug or alcohol abuse or
psychotic disorders; previous treatment with basil-
iximab; use of any investigational drug within 30
days before the visit on day 1; a donor age of more
than 60 years or less than 6 years; a donor whose
r
methods
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heart was not beating at the time of organ harvest;




The primary objective was to demonstrate that be-
latacept was not inferior to cyclosporine in its ability
to prevent rejection at six months. Acute rejection,
defined clinicopathologically, required an increase
in the serum creatinine level of at least 0.5 mg per
deciliter (44.2 µmol per liter) over prerejection base-
line levels in the absence of other confounding fac-
tors and findings on renal biopsy consistent with
the presence of acute rejection (as defined by the





 Patients who had had one
episode of rejection by month 6 were considered to
have reached the primary end point. A sensitivity
analysis was performed with the use of less strin-
gent clinical criteria (an increase in serum creati-
nine levels of at least 0.3 mg per deciliter [26.5 µmol
per liter]). Subclinical rejection was defined by find-
ings on renal biopsy consistent with the presence
of acute rejection (according to the Banff 97 crite-
ria), without an increase in the serum creatinine lev-
el of at least 0.5 mg per deciliter.
Secondary end points were the incidence of
acute rejection (biopsy-confirmed or presumed) at
6 months and 1 year; the measured glomerular fil-
tration rate, as determined by iohexol clearance, at
1, 6, and 12 months; the prevalence of hyperten-
sion; serum cholesterol and triglyceride levels; and
overall safety. Other prespecified analyses included
the rate of death or graft loss at one year; the inci-
dence of post-transplantation diabetes mellitus (de-
fined as the need for therapy for hyperglycemia for
at least four weeks or a glycosylated hemoglobin val-
ue greater than 7 percent in patients not previous-
ly known to have diabetes); the calculated glomeru-
lar filtration rate, as determined by the Modification


















; pharmacokinetics; and im-
munogenicity. A post hoc analysis was conducted of
the incidence of chronic allograft nephropathy (ac-
cording to the Banff 97 criteria). In addition, a post
hoc analysis of patients who had treatment for hy-





Patients were randomly assigned in equal num-
bers to receive an intensive regimen of belatacept,
a less-intensive regimen of belatacept, or cyclospor-
ine (Neoral, Novartis) for primary maintenance im-
munosuppression (Fig. 1). Randomization was per-
formed centrally. Both belatacept regimens included
an early phase (10 mg of belatacept per kilogram
of body weight) and a late phase (5 mg of belata-
cept per kilogram at four-week or eight-week inter-
vals). Doses, based on body weight, were dictated
by trough profiles shown to be effective in studies
of nonhuman primates. This approach necessi-
tated the use of higher doses during the period of
greatest immunologic risk (day 0 through day 90).
The early phase was longer in the intensive regimen
(six months vs. three months) and included more
frequent dosing. Belatacept was administered as
a 30-minute intravenous infusion. The dose of cy-
closporine was chosen to achieve prespecified rang-
es of serum levels (Fig. 1). Because of the require-
ment for therapeutic monitoring and adjustments
in dose, cyclosporine was administered in an un-
blinded fashion.
All patients received induction therapy with
20 mg of basiliximab (Simulect, Novartis) on day 0
and day 4, 2 g of mycophenolate mofetil (CellCept,
Roche) daily, and a corticosteroid-tapering regi-
men, consisting of an intravenous bolus of 500 mg
of methylprednisolone on day 1 and 250 mg on
day 2, followed by 100 mg of oral prednisone on
day 3, 50 mg on day 4, 25 mg on days 5 through 30,
22.5 mg on days 31 through 44, 20 mg on days 45
through 58, 17.5 mg on days 59 through 72, 15 mg
on days 73 through 86, 12.5 mg on days 87 through
100, and 10 mg on days 101 through 114. After day
114, the dose could be decreased by 2.5 mg every
other month but not to less than 5 mg per day.
Episodes of acute rejection of Banff 97 grade IIA
or less were treated with bolus corticosteroids. Cor-
ticosteroid-resistant episodes or episodes of at least
grade IIB were treated with antibody therapy.
 
renal biopsy and measurement 
of glomerular filtration rate
 
Renal biopsy was performed at baseline (intraop-
eratively) and at month 12. Additional biopsy spec-
imens were obtained as needed to diagnose acute
rejection and to evaluate a patient’s response to anti-
rejection therapy. All biopsy specimens were exam-
ined locally as well as centrally by a single histopa-
thologist according to Banff 97 criteria in a blinded
fashion. Results of the central interpretation were
used for all analyses.
The glomerular filtration rate was measured at
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months 1, 6, and 12 by determining the rate of dis-
appearance from the plasma of a 5-ml bolus of
unlabeled iohexol over a period of four hours.
Samples were analyzed at a central facility. The glo-
merular filtration rate was estimated with the use




Primary efficacy analyses were performed accord-
ing to the intention to treat with the use of data
from all patients who underwent randomization
and transplantation. The primary efficacy varia-
ble was summarized within and between treatment
groups with the use of point estimates and 95 per-
cent confidence intervals. For the primary efficacy
end point, the upper bound of the 95 percent confi-
dence interval around the treatment difference had
to be less than 20 percent for belatacept to be con-
sidered noninferior to cyclosporine. Assuming a
15 percent rate of clinically suspected, biopsy-prov-
en episodes of acute rejection and a 10 percent
dropout rate, we determined that 70 patients were
required in each treatment group for the study to
have a statistical power of 85 percent. For other
analyses, no statistical hypotheses were prespeci-
fied, and descriptive summaries are provided.
 
characteristics and disposition 
of the patients
 
A total of 218 patients underwent randomization
and transplantation: 74 were assigned to receive
intensive belatacept, 71 to receive less-intensive
belatacept, and 73 to receive cyclosporine. Two pa-
tients assigned to receive cyclosporine did not re-
ceive a single dose and thus were not included in
safety analyses. Baseline demographic and clini-
cal characteristics were similar among the groups
(Table 1). The rates of discontinuation were also
similar: 16 patients discontinued intensive belata-
cept, 16 discontinued less-intensive belatacept, and
20 discontinued cyclosporine. A total of 164 pa-




The incidence of acute rejection at six months was
similar among the groups and satisfied noninfe-
riority criteria as predefined: 7 percent in the group
receiving-intensive belatacept, 6 percent in the group
receiving less-intensive belatacept, and 8 percent
in the cyclosporine group (absolute difference
between intensive therapy and cyclosporine, ¡1.5
percentage points [95 percent confidence interval,
¡11.3 to 8.3 percentage points], and absolute dif-
ference between less-intensive therapy and cyclo-
sporine, ¡2.6 percentage points [95 percent confi-
dence interval, ¡12.3 to 6.7 percentage points])
(Table 2). No episodes of acute rejection were re-
ported after month 6 in any group. Episodes of re-
jection were more frequent when an increase in the
serum creatinine level of at least 0.3 mg per decili-
ter was used as a criterion, but the incidence was
similar among the groups (9 percent in the group
receiving intensive belatacept, 8 percent in the group
receiving less-intensive belatacept, and 11 percent
in the cyclosporine group). Episodes of rejection
results
 
Figure 1. Study Design and Dosing Regimen.
 
The dose of cyclosporine was chosen to achieve prespecified ranges of serum 
levels. All patients received induction therapy with basiliximab, adjunctive 






10 mg/kg on days
1, 5, 15, 29, 43,
57, 71, 85
4 – 6 Mo















71 Assigned to less-
intensive belatacept
0 –1 Mo
10 mg/kg on days
1, 15, 29
2–3 Mo




4 or 8 wk
193 Low-risk patients (89%)
Patients receiving 1st renal
transplant
Patients with a history of panel-
reactive antibody titer of ≤20%
Patients at low risk for acute
rejection (investigator
determined)
25 High-risk patients (11%)
Patients receiving 2nd or
subsequent renal transplant
Patients with a history of a panel-
reactive antibody titer of >20%
Patients at increased risk for acute
rejection (investigator
determined)
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of at least grade IIB, requiring use of antilympho-
cyte antibody preparations, were infrequent in all
the groups: 4 percent in the group receiving inten-
sive belatacept, 7 percent in the group receiving less-
intensive belatacept, and 3 percent in the cyclo-
sporine group. These instances of rejection were
identified whether or not there was a clinical sus-
picion of rejection. Acute rejection contributed to
two graft losses, one in the intensive-therapy group
and one in the cyclosporine group. The incidence of
secondary end points of biopsy-proven or presumed
acute rejection at six months was similar among the
groups (11 percent in the intensive-therapy group,
8 percent in the group receiving less-intensive thera-
py, and 10 percent in the cyclosporine group). Sub-
clinical rejection at month 6 was more common
with less-intensive belatacept (20 percent) than
with intensive belatacept (9 percent) or cyclospor-
ine (11 percent) (Table 2). Episodes of subclinical
rejection were generally grade IIA or lower and were




The measured glomerular filtration rate at 12
months was significantly higher among patients
receiving the intensive and less-intensive belatacept
regimens than among those receiving cyclospor-





respectively; P=0.01 for the comparison between
intensive belatacept and cyclosporine and P=0.04
between less-intensive belatacept and cyclospor-
ine) (Table 3). The Modification of Diet in Renal
Disease method of estimating the glomerular fil-
tration rate provided the best correlations between




By month 12, the incidence of chronic allograft
nephropathy was lower among patients receiving
belatacept than among those receiving cyclospor-
ine: 29 percent in the group receiving intensive
belatacept, 20 percent in the group receiving less-
intensive belatacept, and 44 percent in the cyclo-
 
* Because of rounding, percentages may not total 100.













Age (yr)† 46.5 42.1 46.1
Sex (%)
Male 73 68 67
Female 27 32 33
Race or ethnic group (%)‡
White 86 80 81
Black 8 9 8
Other 6 11 11
Cause of end-stage renal disease (%)
Glomerulonephritis 30 28 19
Diabetes 7 9 14
Hypertension 10 11 4
Repeated transplantation or graft failure 0 1 0
Other 54 51 63
Deceased donor (%) 69 73 78
Mean duration of cold ischemia (hr) 20 20 18
Most recent panel reactive antibody titer ≥20% (%) 1 3 1
≥1 Prior transplantations (%) 1 6 3
>3 HLA mismatches (%) 42 41 40
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITAT DE BARCELONA CRAI on July 2, 2014. For personal use only. No other uses without permission. 
 Copyright © 2005 Massachusetts Medical Society. All rights reserved. 
 












sporine group (Table 3). Among patients with
chronic allograft nephropathy, the calculated glo-
merular filtration rate was higher in both belata-
cept groups than in the cyclosporine group.
 
patient and allograft survival
 
Four patients in the cyclosporine group died, and
one patient in the intensive-belatacept group died.
Two of the four patients who died in the cyclospor-
ine group died of cardiac causes. Graft loss among
the surviving patients was infrequent — occurring
in three patients receiving intensive belatacept, one
receiving less-intensive belatacept, and two receiv-
ing cyclosporine — and was most commonly due
to technical reasons, such as renal-vein or renal-




Safety summaries are based on reports of new or
worsening adverse events, as determined by the in-
vestigators. Adverse events whose frequency was at
least 5 percentage points higher in the cyclospor-
ine group than in either belatacept group included
leukopenia, anemia, edema, hypertension, urinary
tract infection, hypokalemia, hypomagnesemia, ac-
idosis, tremor, hypertrichosis, and diabetes melli-
tus (Table 5). Episodes of rejection reported by in-
vestigators as an adverse event were the only adverse
event whose frequency was at least 5 percentage
points higher in both belatacept groups than in the
cyclosporine group: 26 percent in the group receiv-
ing intensive belatacept, 32 percent in the group
receiving less-intensive belatacept, and 16 percent
in the cyclosporine group (P=0.06). Some suspect-
ed episodes of transplant rejection included in
this analysis were later determined by adjudica-
tion not to represent actual episodes of acute re-
jection. The events confirmed by adjudication were
included in the primary efficacy analysis, which
showed similar rates of acute rejection in the three
groups (Table 2). To date, no clinically significant
adverse events had been reported during infusions
of belatacept either in the original trial or during
follow-up.
The frequency of infection was similar among
the groups: 73 percent in both belatacept groups
and 75 percent in the cyclosporine group. The most
common were urinary tract infections (23 percent
in the group receiving intensive therapy, 24 percent
in the group receiving less-intensive therapy, and
31 percent in the cyclosporine group) and cytomeg-
alovirus infections (15 percent, 14 percent, and 18
percent, respectively).
Cancer occurred in two patients treated with in-
tensive belatacept (one had breast cancer, and one
had post-transplantation lymphoproliferative dis-
order) and in two patients treated with cyclosporine
(one had skin cancer, and one had thyroid cancer).
However, post-transplantation lymphoprolifera-
tive disorder developed in two additional patients
treated with the intensive regimen 2 and 13 months
after belatacept had been replaced with convention-
 
* CI denotes confidence interval.
 









Primary efficacy end point
Clinically suspected and biopsy-proven acute 
rejection at 6 mo — no. (%)
5 (7) 4 (6) 6 (8)
Absolute difference in rate from cyclosporine 
group — percentage points (exact 95% CI)*
¡1.5 (¡11.3 to 8.3) ¡2.6 (¡12.3 to 6.7) —
Secondary efficacy end points
Mild acute rejection (grade IA) — no. (%) 2 (3) 0 1 (1)
Mild acute rejection (grade IB) — no. (%) 0 0 1 (1)
Moderate acute rejection (grade IIA) — no. (%) 2 (3) 3 (4) 2 (3)
Moderate acute rejection (grade IIB) — no. (%) 1 (1) 1 (1) 2 (3)
Subclinical rejection — no. (%) 7 (9) 14 (20) 8 (11)
Treated episode of subclinical rejection 
— no. (%)
6 (8) 11 (15) 5 (7)
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al immunosuppressive agents (tacrolimus, myco-
phenolate mofetil, and corticosteroids). Of the three
patients in whom post-transplantation lymphopro-
liferative disorder developed, two had primary Ep-
stein–Barr virus infections. The third had received
a 10-day course of muromonab-CD3 for acute rejec-
tion, and belatacept had been discontinued just be-
fore this therapy was administered; post-transplan-
tation lymphoproliferative disorder was diagnosed
13 months later. Approximately half the patients
were enrolled voluntarily in a long-term extension
of the protocol; no additional cases of post-trans-
plantation lymphoproliferative disorder were re-
ported among patients treated for up to four years
with belatacept.
 
cardiovascular and metabolic effects
 
At 12 months, the mean (±SD) total cholesterol lev-
els were similar among the groups, at 198±41 mg
per deciliter (5±1 mmol per liter) in the group re-
ceiving intensive belatacept, 201±40 mg per decili-
ter (5±1 mmol per liter) in the group receiving less-
intensive belatacept, and 212±44 mg per deciliter
(5±1 mmol per liter [1±0 mmol per liter]) in the cy-
closporine group. Mean levels of high-density lipo-
protein cholesterol were also similar among the
groups (53±16 mg per deciliter [1.4±0.4 mmol
per liter] in the group receiving intensive belata-
cept, 56±14 mg per deciliter [1.4±0.4 mmol per
liter] in the group receiving less-intensive belata-
cept, and 59±18 mg per deciliter [1.5±0.5 mmol
 
* Plus–minus values are means ±SD. GFR denotes glomerular filtration rate, CI confidence interval, and CAN chronic al-
lograft nephropathy.
† P<0.05 for the comparison of both belatacept regimens with cyclosporine. 
 
‡ Patients in this group underwent at least one biopsy after baseline.
 
Table 3. Renal Function and Histologic Findings.*





No. of patients 32 37 27




† 66.3±20.7 62.1±15.9 53.5±16.4










No. of patients 52 54 45
CAN at 12 mo — no. (% [95% CI])‡ 15 (29 [16.5 to 41.2]) 11 (20 [9.6 to 31.1]) 20 (44 [29.0 to 59.0])
Mild CAN (stage I) — no. (%) 11 (21) 6 (11) 16 (36)
Moderate CAN (stage II) — no. (%) 4 (8) 1 (2) 3 (7)
Severe CAN (stage III) — no. (%) 0 4 (7) 1 (2)
Absolute difference in rate from cyclosporine 
group — percentage points (asymptotic 
exact 95% CI)




No. of patients 60 59 50











4.4 (¡5.2 to 14.0) 5.2 (¡4.4 to 14.8) —
No. of patients without CAN 49 50 37











¡0.7 (¡10.5 to 9.1) ¡3.4 (¡12.8 to 6.0) —
No. of patients with CAN 11 9 13











13.3 (¡6.2 to 32.8) 29.5 (3.2 to 55.8) —
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per liter] in the cyclosporine group), as were the
mean levels of low-density lipoprotein cholester-
ol (145±37 mg per deciliter [4±1 mmol per liter],
144±36 mg per deciliter [4±1 mmol per liter], and
151±43 mg per deciliter [4±1 mmol per liter], re-
spectively). However, more patients in the cyclo-
sporine group than in either belatacept group were
receiving lipid-lowering medications (53 percent,
as compared with 36 percent in the intensive-ther-
apy group and 32 percent in the group given less-
intensive therapy; P=0.03 for the comparison with
both belatacept groups).
Systolic blood pressure at 12 months was 3 or
4 mm Hg higher among patients receiving cyclo-
sporine than among patients receiving belatacept,
whereas diastolic blood pressure levels were sim-
ilar among the groups. A post hoc analysis of the
prevalence of hypertension requiring treatment at
12 months was 88 percent in the intensive-belata-
cept group, 83 percent in the group receiving less-
intensive belatacept, and 92 percent in the cyclo-
sporine group. Diabetes mellitus was infrequent
after transplantation, occurring in 12 percent of pa-
tients in the group receiving intensive therapy, 6 per-
cent of those in the group receiving less-intensive
therapy, and 12 percent of those in the cyclospor-
ine group. 
The primary objective of this study was to demon-
strate the noninferiority of belatacept over cyclo-
sporine with respect to the incidence of acute rejec-
tion at six months. Our results suggest that the two
agents are similarly effective for the prevention of
acute rejection. Patients treated with belatacept reg-
imens had rates of acute rejection similar to those
among patients taking cyclosporine, satisfying pre-
specified criteria for noninferiority. The observed
rates of acute rejection of 6 to 7 percent with belata-
cept, mycophenolate mofetil, corticosteroids, and
basiliximab in this trial compare favorably with
rates of 8 to 17 percent reported in clinical trials of





 and are lower than the
rate of 47 percent reported in a clinical trial of my-
discussion
 
* CI denotes confidence interval, and PTLD post-transplantation lymphoproliferative disorder.
† The cause of infarction was unknown but may have been indicative of ongoing rejection.
‡ Patients may have had a combination of persistent delayed graft function, acute rejection, and infection.
 
§ One patient had graft loss and subsequently died.
 








Death at 12 mo 
 
Total — no. (%) 1 (1) 0 4 (5)
Reason — no. (%)
Cardiac causes 0 0 2 (3)
Infection or sepsis 1 (1) 0 0 
Pulmonary embolism 0 0 1 (1)
Other or unknown 0 0 1 (1)
 
Graft loss at 12 mo
 
Total — no. (%) 3 (4) 1 (1) 2 (3)
Reason — no. (%)
Renal-vein or renal-artery thrombosis 1 (1) 1 (1) 2 (3)
Infarction† 1 (1) 0 0 
Treatment of PTLD 1 (1) 0 0 
Combination‡ 0 0 1 (1)
 
Death or graft loss at 12 mo 
 
Total — no. (%) 4 (5) 1 (1) 6 (8)§
Absolute difference from cyclosporine group 
— percentage points (95% CI)
¡2.8 (¡11.0 to 5.3) ¡6.8 (¡13.7 to 0.1) —
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* CI denotes confidence interval.
 
Table 5. Incidence of Adverse Events.*
Adverse Event Intensive Belatacept
Less-Intensive




Absolute difference from cyclosporine group 
— percentage points (95% CI)
19
¡10.7 (¡24.5 to 3.2)
17






Absolute difference from cyclosporine group 
— percentage points (95% CI)
18
¡12.0 (¡25.7 to 1.7)
17






Absolute difference from cyclosporine group 
— percentage points (95% CI)
8
¡7.4 (¡17.9 to 3.1)
10






Absolute difference from cyclosporine group 
— percentage points (95% CI)
22
¡9.4 (¡23.6 to 4.9)
24






Absolute difference from cyclosporine group 
— percentage points (95% CI)
23
¡8.0 (¡22.4 to 6.4)
24






Absolute difference from cyclosporine group 
— percentage points (95% CI)
7
¡5.9 (¡15.5 to 3.7)
7






Absolute difference from cyclosporine group 
— percentage points (95% CI)
3
¡7.2 (¡15.0 to 0.7)
4






Absolute difference from cyclosporine group 
— percentage points (95% CI)
4
¡5.8 (¡14.1 to 2.5)
1






Absolute difference from cyclosporine group 
— percentage points (95% CI)
11
¡8.9 (¡20.6 to 2.7)
14






Absolute difference from cyclosporine group 
— percentage points (95% CI)
0
¡5.6 (¡11.0 to 0.3)
0






Absolute difference from cyclosporine group 
— percentage points (95% CI)
1
¡7.1 (¡14.1 to ¡0.1)
1






Absolute difference from cyclosporine group 
— percentage points (95% CI)
12
+3.7 (¡6.2 to 13.6)
11
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cophenolate mofetil, corticosteroids, and daclizu-




Our results imply that the use of belatacept may
allow patients to avoid the adverse renal, cardiovas-
cular, and metabolic effects of cyclosporine. The
measured glomerular filtration rate at one year was
approximately 9 to 13 ml per minute higher among
recipients of belatacept than among cyclosporine
recipients. Since the glomerular filtration rate gen-





 per year in transplant recipients, these
differences, if sustained, could result in improved





scoring the potential benefit of non-nephrotoxic
therapy, we found differences in the calculated glo-
merular filtration rate favoring belatacept in pa-
tients with chronic allograft nephropathy. Mea-
sured cholesterol levels and blood pressure were
similar or slightly lower in the belatacept groups
than in the cyclosporine group, despite the greater
use of lipid-lowering and antihypertensive therapy
among patients receiving cyclosporine.
Long-term immunosuppression increases the
risks of infection and cancer. We found a similar
rate of infections among the groups. Likewise,
the frequency of cancer was similar, occurring in
2 of 145 patients in the belatacept groups during
treatment (1 percent) and 4 of 145 overall (3 per-
cent) and 2 of 71 patients in the cyclosporine group
(3 percent). The rate of cancer with belatacept was
consistent with the estimated incidence of 3.3 per-






to occur in the belatacept groups in a dose-depen-





 There were three
cases of post-transplantation lymphoproliferative
disorder, a well-recognized complication of organ
transplantation with reported incidence rates of





 and up to 2.9 percent in large, multi-





 All cases of post-transplantation lympho-
proliferative disorder were associated with either
primary Epstein–Barr virus infection or treatment
with muromonab-CD3, both of which are known




 Two cases oc-
curred after the discontinuation of belatacept; it
is not possible to determine whether these cases
reflect remote effects of belatacept, the effect of
immunosuppressive agents that replaced it, or a
combination of the two. The occurrence of post-
transplantation lymphoproliferative disorder in
patients receiving the intensive, but not the less-
intensive, regimen of belatacept is also consistent





 in which post-transplantation lym-





 A long-term, open-label
extension of our trial is being conducted, and pa-
tients have been treated with belatacept for up to
four years, and no additional cases of post-trans-
plantation lymphoproliferative disorder have been
reported to date.
Subclinical rejection was found more often
among patients receiving the less-intensive regi-
men of belatacept than among those receiving ei-
ther intensive belatacept therapy or cyclosporine.
The findings in the literature concerning the clini-





 In our study, subclinical rejection did not
appear to have an adverse effect on graft survival,
renal function, or the risk of chronic allograft ne-
phropathy in the group receiving less-intensive
therapy.
The differences we identified between belata-
cept and cyclosporine therapy should be regarded
as suggestive rather than definitive. Two specific
issues in the design and conduct of this study
should be noted. First, although prespecified cri-
teria for noninferiority were met and acute rejec-
tion was less common with belatacept than with
cyclosporine, the noninferiority bounds were rela-
tively broad. Owing to the partially blinded trial de-
sign, renal-biopsy specimens were obtained approx-
imately 10 percent more frequently among patients
assigned to belatacept than among patients as-
signed to cyclosporine, a difference that may have
biased biopsy-based evaluations against belatacept
to some degree.
Second, because of a substantial amount of miss-
ing data on the measured glomerular filtration rate,
findings of improved renal function with belata-
cept should be regarded as preliminary. Measure-
ment of the glomerular filtration rate with the use
of reference methods (renal clearance or rate of dis-





 Several formulas were used to estimate
the glomerular filtration rate on the basis of serum
creatinine levels, since this information was more
consistently available.
Belatacept is administered intermittently by in-
fusion, in contrast to calcineurin inhibitors, which
are administered orally each day. Although the ad-
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ministration of monthly infusions requires month-
ly visits to a treatment center, it may lead to improved
compliance, since nonadherence to the belatacept
regimen becomes obvious when the first appoint-
ment is missed.
Improved preservation of renal function has
been reported with the use of sirolimus- or myco-





 Unlike the belatacept regi-
mens we used, in these other studies, concurrent
use of cyclosporine was required for two to four
months, then withdrawn in patients meeting the
study criteria of a low-to-moderate immunologic
risk of rejection. Belatacept therapy does not re-
quire concurrent cyclosporine therapy and has
no restrictions based on a predefined immuno-
logic risk of rejection. Other studies evaluated cal-





 Although these studies
showed preservation of renal function, they also
found a range of rates of initial rejection and, in
one study, more severe rejection or were compli-
cated by high dropout rates, limiting the applica-




Belatacept represents a new class of primary
immunosuppressants, arguably the first since the
introduction of cyclosporine, the first calcineurin
inhibitor. Whereas calcineurin inhibitors block or
diminish the effects of T-cell activation on allografts,
belatacept prevents T-cell activation. This effect is
accomplished without concurrent global immuno-
suppression of T-cell–depletion strategies. Our re-
sults suggest that belatacept can provide a level of
immunosuppressive efficacy in renal-transplant
recipients similar to that afforded by cyclosporine,
but with the potential benefits of improved cardio-
vascular and metabolic risk profiles, greater pres-
ervation of kidney function, and a lower incidence
of chronic allograft nephropathy.
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